Cargando…

(125)Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up

Data from 305 Japanese men with low-risk (n = 175) or intermediate-risk (n = 130) prostate cancer who underwent (125)I monotherapy were retrospectively analyzed. Of the 305 patients, 93 received hormonal therapy for a median of 6 months (range, 1–33 months) before implantation. The prescribed dose t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sekiguchi, Akane, Ishiyama, Hiromichi, Satoh, Takefumi, Tabata, Kenichi, Komori, Shouko, Tsumura, Hideyasu, Kawakami, Shogo, Soda, Itaru, Iwamura, Masatsugu, Hayakawa, Kazushige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951075/ https://www.ncbi.nlm.nih.gov/pubmed/24105711 http://dx.doi.org/10.1093/jrr/rrt113

Ejemplares similares

Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer
por: Ishiyama, Hiromichi, et al.
Publicado: (2015)

A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial
por: Ishiyama, Hiromichi, et al.
Publicado: (2018)

Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patients
por: Kawakami, Shogo, et al.
Publicado: (2014)

Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy
por: Kawakami, Shogo, et al.
Publicado: (2017)

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up
por: Ishiyama, Hiromichi, et al.
Publicado: (2014)

Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2016)

A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
por: Kainuma, Takuro, et al.
Publicado: (2019)

Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2017)

Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?
por: Soda, Itaru, et al.
Publicado: (2015)

Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
por: Fujii, Kyohei, et al.
Publicado: (2023)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer
por: Hayakawa, Toyokazu, et al.
Publicado: (2019)

A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
por: Kawakami, S., et al.
Publicado: (2022)

Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer
por: Yanagisawa, Nobuyuki, et al.
Publicado: (2021)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy
por: Ishiyama, Hiromichi, et al.
Publicado: (2022)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system
por: Katoh, Norio, et al.
Publicado: (2017)

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer
por: Slevin, Finbar, et al.
Publicado: (2020)

Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer
por: Mori, Kohei, et al.
Publicado: (2023)

Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer
por: Inoue, Yusuke, et al.
Publicado: (2014)

The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy
por: Burchardt, Wojciech M., et al.
Publicado: (2023)

Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
por: Ishiyama, Hiromichi, et al.
Publicado: (2021)

Iodine-125 brachytherapy for brain tumours - a review
por: Schwarz, Silke B, et al.
Publicado: (2012)

Iodine-125 seed implantation in the treatment of malignant tumors
por: Hu, Pan, et al.
Publicado: (2023)

Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model
por: Brun, Thomas, et al.
Publicado: (2018)

A Case of Iodine 125 Seeds (I-125) Responding to Lung Squamous Cell Carcinoma
por: Ni, Qingtao, et al.
Publicado: (2022)

Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging
por: Chrastina, Adrian, et al.
Publicado: (2010)

A Robust Oxygen Microbubble Radiosensitizer for Iodine‐125 Brachytherapy
por: Peng, Sheng, et al.
Publicado: (2021)

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions
por: Wei, Shuhua, et al.
Publicado: (2021)

Histopathology of Intraocular Medulloepithelioma following Iodine-125 Plaque Brachytherapy
por: Mohan, Sukriti, et al.
Publicado: (2022)

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma
por: Wang, Congxiao, et al.
Publicado: (2022)

Comparison of Iodine-125 Seed Implantation and Pancreaticoduodenectomy in the Treatment of Pancreatic Cancer
por: Liu, Kai, et al.
Publicado: (2014)

Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy
por: Fang, Rui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cii9mh88re6i4kc9opeplu869k